These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15940218)

  • 1. Acquisition signals shift from US market.
    Mitchell P
    Nat Biotechnol; 2005 Jun; 23(6):635. PubMed ID: 15940218
    [No Abstract]   [Full Text] [Related]  

  • 2. Investment indicators show US is still ahead.
    Lähteenmäki R; Hodgson J
    Nat Biotechnol; 1998 Feb; 16(2):149-50. PubMed ID: 9487519
    [No Abstract]   [Full Text] [Related]  

  • 3. IPO floodgates unlikely to open after Ark floatation.
    Louët S
    Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 5. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 6. Premier funds biotechnology.
    Scott L
    Mod Healthc; 1996 Apr; 26(18):50. PubMed ID: 10157168
    [No Abstract]   [Full Text] [Related]  

  • 7. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotechnology. Another major deal.
    Gershon D
    Nature; 1991 Sep; 353(6342):291. PubMed ID: 1922330
    [No Abstract]   [Full Text] [Related]  

  • 9. US drug industry's research support.
    Clemmitt M
    Nature; 1993 Feb; 361(6414):757-60. PubMed ID: 8441474
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology--the enormous cost of success.
    Levy R
    N Engl J Med; 1991 Oct; 325(16):1177-8. PubMed ID: 1891031
    [No Abstract]   [Full Text] [Related]  

  • 12. Growth in R&D investment holding up.
    Chipman A
    Nature; 2009 Nov; 462(7271):264. PubMed ID: 19924181
    [No Abstract]   [Full Text] [Related]  

  • 13. Market access for biopharmaceuticals: new challenges.
    Simon F
    Health Aff (Millwood); 2006; 25(5):1363-70. PubMed ID: 16966734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will this experiment work?
    Kadlec D
    Time; 2003 Jul; 162(1):80-1. PubMed ID: 14584341
    [No Abstract]   [Full Text] [Related]  

  • 15. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 16. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetus and Chiron merge.
    Gershon D
    Nature; 1991 Aug; 352(6334):364. PubMed ID: 1861710
    [No Abstract]   [Full Text] [Related]  

  • 18. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 19. The lengthening handshake.
    Osborne R
    Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
    [No Abstract]   [Full Text] [Related]  

  • 20. Industry warily eyes new Medicare drug plan.
    Vastag B
    Nat Biotechnol; 2006 Feb; 24(2):120. PubMed ID: 16465141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.